Serum Biomarkers Improve Preeclampsia Screening

The study involved 16,747 women between 11 and 13 weeks’ gestation who were assessed. The new screening method being evaluated in SPREE included not only maternal characteristics but also measurement of different combinations of mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI), serum placental growth factor (PlGF), and serum pregnancy-associated plasma protein-A (PAPP-A).

Maternal serum concentrations of PAPP‐A and PlGF were measured using one of two automated devices: DELFIA Xpress analyzer or the BRAHMS KRYPTOR analyzer. In all, 2.8% of participants developed preeclampsia; just 0.8% developed preterm preeclampsia, defined as requiring delivery before 37 weeks. The standard recommended method screened positive for 30.4% and 40.8% of all preeclampsia and preterm preeclampsia cases, respectively. In contrast, the new method combining maternal characteristics, MAP, and PAPP-A screened positive for 42.5% of all preeclampsia cases. Including PlGF and UtA-PI screened positive for 82.4% of all preterm preeclampsia cases.

The authors concluded that the performance of screening is substantially improved by a method combining maternal factors with biomarkers. Liona Poon, MD, a clinical senior lecturer and co-author of the study, said, “The SPREE study has provided definitive proof to support risk-based screening for preterm-preeclampsia using various biomarkers. It is now time to revise the professional guidelines and to move away from using a checklist-based method for screening.” The study was published originally published online on March 14, 2018, in the journal Ultrasound in Obstetrics Gynecology.

Related Links:
King's College Hospital